Compare INDP & AIHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INDP | AIHS |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.7M |
| IPO Year | 2021 | 2017 |
| Metric | INDP | AIHS |
|---|---|---|
| Price | $2.41 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 67.1K | 14.4K |
| Earning Date | 05-11-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.63 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,389,072.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.27 | $0.25 |
| 52 Week High | $13.24 | $8.26 |
| Indicator | INDP | AIHS |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 43.35 |
| Support Level | $2.36 | $1.10 |
| Resistance Level | $3.11 | $1.28 |
| Average True Range (ATR) | 0.41 | 0.10 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 25.71 | 16.63 |
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.